$BRQL
brooqLy, Inc.

2022 Q2 Form 10-Q Financial Statement

#000147793222003429 Filed on May 16, 2022

View on sec.gov

Income Statement

Concept 2022 Q2 2022 Q1 2021 Q1
Revenue $661.00 $115.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $49.59K $66.83K $4.925K
YoY Change 78.85% 1256.89%
Operating Profit -$48.93K -$66.71K -$4.925K
YoY Change 76.46% 1254.56%
Interest Expense $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$48.93K -$66.71K -$4.925K
YoY Change 76.46% 1254.56%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$48.93K -$66.71K -$4.925K
YoY Change 76.46% 1254.56%
Net Earnings / Revenue -7401.82% -58010.43%
Basic Earnings Per Share
Diluted Earnings Per Share
COMMON SHARES
Basic Shares Outstanding 21.69M shares 22.57M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2022 Q2 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $5.543K $3.184K $0.00
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets
Total Long-Term Assets
Total Assets
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$404.9K
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.05K $3.976K -$4.925K
YoY Change
Total Liabilities & Shareholders Equity $76.90K
YoY Change

Cashflow Statement

Concept 2022 Q2 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$48.93K -$66.71K -$4.925K
YoY Change 76.46% 1254.56%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$31.60K $0.00
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$8.250K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $13.00K $0.00
YoY Change
NET CHANGE
Cash From Operating Activities -$31.60K $0.00
Cash From Investing Activities -$8.250K $0.00
Cash From Financing Activities $13.00K $0.00
Net Change In Cash -$26.85K $0.00
YoY Change
FREE CASH FLOW
Cash From Operating Activities -$31.60K $0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21689982 shares
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21689982 shares
CY2021Q4 brooqly Common Stock Share Outstanding
CommonStockShareOutstanding
22564982 shares
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
265500 USD
CY2022Q1 us-gaap Revenues
Revenues
115 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8250 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2022Q1 brooqly Shares Issued For Cash
SharesIssuedForCash
12999 USD
CY2021Q1 brooqly Shares Issued For Cash
SharesIssuedForCash
0 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12999 USD
CY2022Q1 us-gaap Professional Fees
ProfessionalFees
47014 USD
CY2021Q1 us-gaap Professional Fees
ProfessionalFees
4065 USD
CY2022Q1 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
19813 USD
CY2021Q1 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
860 USD
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
66827 USD
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
4925 USD
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-66712 USD
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4925 USD
CY2022Q1 us-gaap Interest Expense
InterestExpense
0 USD
CY2021Q1 us-gaap Interest Expense
InterestExpense
0 USD
CY2022Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0 USD
CY2021Q1 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
0 USD
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66712 USD
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4925 USD
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-66712 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4925 USD
CY2022Q1 brooqly Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
0.00
CY2021Q1 brooqly Earnings Per Shares Basic And Diluted
EarningsPerSharesBasicAndDiluted
0
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22574075 shares
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-66712 USD
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-4925 USD
CY2022Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
871 USD
CY2021Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
0 USD
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
23963 USD
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
0 USD
CY2022Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
10278 USD
CY2021Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
4925 USD
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31600 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
0 USD
CY2022Q1 brooqly Payment To Software
PaymentToSoftware
-8250 USD
CY2021Q1 brooqly Payment To Software
PaymentToSoftware
0 USD
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-26851 USD
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
0 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30035 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 USD
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3184 USD
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
0 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
57687 USD
CY2022Q1 brooqly Shares Issued For Cash Amount
SharesIssuedForCashAmount
12999 USD
CY2022Q1 brooqly Shares Issued For Services
SharesIssuedForServices
0 USD
CY2022Q1 brooqly Subscription Receivable Shares
SubscriptionReceivableShares
0 USD
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-66712 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
3975 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
0 USD
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-4925 USD
CY2021Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
88000 USD
us-gaap Stock Issued During Period Shares Issued For Services
StockIssuedDuringPeriodSharesIssuedForServices
247482 shares
CY2021 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
49497 USD
CY2022Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of condensed financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue and expenses and disclosure of contingent assets and liabilities at the date the condensed financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
115 USD
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q1 brooqly Common Stock Share Issued
CommonStockShareIssued
21689982 shares
CY2022Q1 brooqly Warrants Issued To Accredited Investor
WarrantsIssuedToAccreditedInvestor
1000000 shares
CY2022Q1 brooqly Purchase Of Common Stock
PurchaseOfCommonStock
1000000 shares
CY2022Q1 brooqly Purchase Of Warrants During Period
PurchaseOfWarrantsDuringPeriod
1000000 shares
CY2022Q1 us-gaap Accelerated Share Repurchases Final Price Paid Per Share
AcceleratedShareRepurchasesFinalPricePaidPerShare
0.10
CY2022Q1 brooqly Desription Of Investment
DesriptionOfInvestment
The investment was in excess of $50,000 entitling the investor to receive shares and warrants at a reduced price instead of at $0.20 per share from those investors investing less than $50,000. The investor failed to pay $75,000 of the aggregate investment and the company has determined that the investor will not receive the benefit of the $0.10 per share price and its shares shall be calculated on the basis of $0.20 per share, for which there is an adjusted number of common shares (and no warrants), of 125,000 shares for the cash proceeds of $25,000 that the company received from the investor.
CY2021Q4 brooqly Number Of Investors
NumberOfInvestors
3 integer
CY2022Q1 brooqly Cancellation Of Common Stock And Warrants
CancellationOfCommonStockAndWarrants
1000000 shares
CY2022Q1 brooqly Payment Made To Investor
PaymentMadeToInvestor
75000 USD
CY2022Q1 brooqly Desription Of Investment
DesriptionOfInvestment
Aggregate Investment; as such, the investment was calculated on the basis of $0.20 per share, for which there is an adjusted number of Common Stock Shares (and no warrants) of 125,000 shares, rather than the 1,000,000 shares. The difference of 875,000 shares (will be cancelled and returned to the Company’s treasury. resulting in a decrease of the Company’s outstanding shares by 875,000 shares.
CY2022Q1 us-gaap Cumulative Earnings Deficit
CumulativeEarningsDeficit
57688 USD
CY2022Q1 brooqly Cancellation Of Common Stock And Warrants
CancellationOfCommonStockAndWarrants
1000000 shares
CY2022Q1 brooqly Number Of Common Stock Sold
NumberOfCommonStockSold
125000 shares
CY2022Q1 brooqly Receipt From Sale Of Common Stock
ReceiptFromSaleOfCommonStock
25000 USD
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
3975 USD
CY2021Q1 us-gaap Cumulative Earnings Deficit
CumulativeEarningsDeficit
0 USD
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-4925 USD
CY2022Q1 brooqly Operating Gain Loss Carryforwards
OperatingGainLossCarryforwards
-356021 USD
CY2021Q4 brooqly Operating Gain Loss Carryforwards
OperatingGainLossCarryforwards
-289309 USD
CY2022Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
356021 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
289309 USD
CY2022Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0 USD
CY2021Q4 brooqly Operating Gain Loss Carryforwards
OperatingGainLossCarryforwards
-289309 USD
CY2022Q1 brooqly Operating Gain Loss Carryforwards
OperatingGainLossCarryforwards
-356021 USD

Files In Submission

Name View Source Status
0001477932-22-003429-index-headers.html Edgar Link pending
0001477932-22-003429-index.html Edgar Link pending
0001477932-22-003429.txt Edgar Link pending
0001477932-22-003429-xbrl.zip Edgar Link pending
brooqly-20220331.xsd Edgar Link pending
brooqly-20220331_cal.xml Edgar Link unprocessable
brooqly-20220331_def.xml Edgar Link unprocessable
brooqly-20220331_lab.xml Edgar Link unprocessable
brooqly-20220331_pre.xml Edgar Link unprocessable
brooqly_10q.htm Edgar Link pending
brooqly_10q_htm.xml Edgar Link completed
brooqly_ex311.htm Edgar Link pending
brooqly_ex312.htm Edgar Link pending
brooqly_ex321.htm Edgar Link pending
brooqly_ex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending